P4P4P: An Agenda for Research on Pay for Performance for Patients

Center for Health Incentives, Leonard Davis Institute of Health Economics, Wharton School, University of Pennsylvania, USA.
Health Affairs (Impact Factor: 4.97). 01/2009; 28(1):206-14. DOI: 10.1377/hlthaff.28.1.206
Source: PubMed


Unhealthy behavior is a major cause of poor health outcomes and high health care costs. In this paper we describe an agenda for research to guide broader use of patient-targeted financial incentives, either in conjunction with provider-targeted financial incentives (pay-for-performance, or P4P) or in clinical contexts where provider-targeted approaches are unlikely to be effective. We discuss evidence of proven effectiveness and limitations of the existing evidence, reasons for underuse of these approaches, and options for achieving wider use. Patient-targeted incentives have great potential, and systematic testing will help determine how they can best be used to improve population health.

Download full-text


Available from: George Loewenstein,
  • Source
    • "Previous research on incentive-based treatments can help researchers and practitioners choose a pragmatic, evidence-based conceptual framework. CM has been the focus of more frequent and systematic empirical investigation than any other incentive-based intervention discussed in the health care literature.23,24 It has been shown to promote abstinence from cocaine,25,26 opiates,27 alcohol,28 tobacco,29,30 marijuana,31 and polydrug use.32 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Behavior plays an important role in health promotion. Exercise, smoking cessation, medication adherence, and other healthy behavior can help prevent, or even treat, some diseases. Consequently, interventions that promote healthy behavior have become increasingly common in health care settings. Many of these interventions award incentives contingent upon preventive health-related behavior. Incentive-based interventions vary considerably along several dimensions, including who is targeted in the intervention, which behavior is targeted, and what type of incentive is used. More research on the quantitative and qualitative features of many of these variables is still needed to inform treatment. However, extensive literature on basic and applied behavior analytic research is currently available to help guide the study and practice of incentive-based treatment in health care. In this integrated review, we discuss how behavior analytic research and theory can help treatment providers design and implement incentive-based interventions that promote healthy behavior.
    Psychology Research and Behavior Management 03/2014; 7:103-114. DOI:10.2147/PRBM.S59792
  • Source
    • "The magnitude of the benefits and the costs from a specific incentive system will depend on the size and structure (e.g. escalating benefits) of the benefits, including: frequency of testing and paying incentives, method of testing for achievement of the outcomes (e.g., cotinine levels vs. self-report) and length of the incentive program and follow-up, among other behavioral factors (Haisley et al., 2012; Volpp et al., 2009b, 2011). Interestingly, higher and more frequent payments, more frequent testing and a longer program all increase effectiveness and benefits. "

    Preventive Medicine 06/2012; 55 Suppl:S116-7. DOI:10.1016/j.ypmed.2012.03.017 · 3.09 Impact Factor
  • Source
    • "Rather, we relied on baseline responses and recall at six months. Reimbursement for transport costs, estimated to be ~25% of the patients' cost of ART[51], may have improved adherence to treatment[52]. In addition, this was a clinical research study in which attention and resources were devoted to reinforcing adherence[53], so it is likely that incomplete adherence may be more prevalent in a routine HIV care setting. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adherence is a necessary part of successful antiretroviral treatment (ART). We assessed risk factors for incomplete adherence among a cohort of HIV-infected women initiating ART and examined associations between adherence and virologic response to ART. A secondary data analysis was conducted on a cohort of 154 women initiating non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART at a single site in Johannesburg, South Africa. Ninety women had been enrolled in a prevention of mother-to-child transmission (pMTCT) program and were exposed to single-dose nevirapine (sdNVP) >18 months earlier. Women were interviewed pre-treatment and clinical, virologic and adherence data were collected during follow-up to 24 weeks. Incomplete adherence to ART was defined as returning >5% of medications, estimated by pill counts at scheduled visits. Multivariable logistic regression analysis and unadjusted odds ratio (95%CI) were performed, using STATA/SE (ver 10.1). About half of the women (53%) were <30 years of age, 63% had <11 years of schooling, 69% were unemployed and 37% lived in a shack. Seven percent of women had a viral load >400 copies/ml at 24 weeks and 37% had incomplete adherence at one or more visits. Incomplete adherence was associated with less education (p = 0.01) and lack of financial support from a partner (p = 0.02) after adjustment for confounders. Only when adherence levels dropped below 80% was there a significant association with viremia in the group overall (p = 0.02) although adherence <95% was associated with viremia in the sdNVP-exposed group (p = 0.03). The main reasons for incomplete adherence were being away from home, busy with other things and forgetting to take their medication. Virologic response to NNRTI-treatment in the cohort was excellent. However, women who received sdNVP were at greater risk of virologic failure when adherence was <95%. Women exposed to sdNVP, and those with less education and less social support may benefit from additional adherence counseling to ensure the long-term success of ART. More than 80% adherence may be sufficient to maintain virologic suppression on NNRTI-based regimens in the short-term, however complete adherence should be encouraged.
    BMC Public Health 02/2011; 11(1):88. DOI:10.1186/1471-2458-11-88 · 2.26 Impact Factor
Show more